白雲山(0874.HK)一度漲6% 股價創逾5個月新高
格隆匯1月3日丨國家醫保局和中醫藥管理局30日發佈《關於醫保支持中醫藥傳承創新發展的指導意見》,港股中藥股繼續走強。其中,近日表現強勢的白雲山今日盤中再度漲6%報23.8港元,股價創2021年7月以來新高。公開資料顯示,白雲山目前主要從事:1)中西成藥、化學原料藥、天然藥物、生物醫藥、化學原料藥中間體的研究開發、製造與銷售;2)西藥、中藥和醫療器械的批發、零售和進出口業務;3)大健康產品的研發、生產與銷售;4)醫療服務、健康管理、養生養老等健康產業投資等。2021年前三季度,白雲山實現營收5354萬元,同比增14.19%;歸屬於母公司股東扣非前和扣非後淨利潤分別為331萬元和329萬元,同期分別增24.55%和33.02%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.